Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer

PURPOSE: To improve the selection of advanced colorectal cancer patients to panitumumab by optimizing the assessment of RAS (KRAS-NRAS) mutations. EXPERIMENTAL DESIGN: Using a centralized pyrosequencing RAS assay, we analyzed the tumors of 94 patients, wild-type for KRAS mutations (codons 12 to 13)...

Full description

Bibliographic Details
Main Authors:	Giampietro Gasparini, Fiamma Buttitta, Mario Rosario D'Andrea, Salvatore Tumolo, Angela Buonadonna, Ida Pavese, Stefano Cordio, Michele De Tursi, Stefania Mosconi, Luciano Stumbo, Lara Felicioni, Antonio Marchetti
Format:	Article
Language:	English
Published:	Elsevier 2014-09-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558614001080

Similar Items

Treatment of metastatic colorectal cancer: focus on panitumumab
by: Tay RY, et al.
Published: (2015-06-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-01-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-02-01)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
by: Pui Lam Yip, et al.
Published: (2023-04-01)

RESULTS OF PANITUMUMAB ADDITION TO CONVERSION THERAPY FOR COLORECTAL CANCER LIVER METASTASES
by: M. I. Sekacheva, et al.
Published: (2015-02-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
by: Shigemasa Takamizawa, et al.
Published: (2021-02-01)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
by: Hiroya Taniguchi, et al.
Published: (2018-07-01)

Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer
by: Mauro Moroni, et al.
Published: (2021-08-01)

Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study
by: Lakomy R, et al.
Published: (2015-10-01)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Panitumumab-Induced Periorbital Dermatitis: A Case Report
by: Pongbangpho N, et al.
Published: (2024-04-01)

Mutational profile of GNAQQ209 in human tumors.
by: Simona Lamba, et al.
Published: (2009-08-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Cancer therapy related cardiac dysfunction as a result of Panitumumab
by: Isabelle Senechal, et al.
Published: (2024-04-01)

Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
by: Seymour, M, et al.
Published: (2011)

PRIDE syndrome associated with panitumumab treatment – case report and literature review
by: Magalena Pałdyna, et al.
Published: (2023-05-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma
by: Paulo Ricardo Saquete Martins-Filho, et al.
Published: (2013-01-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.
by: Antonio Marchetti, et al.
Published: (2012-01-01)

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
by: Mareike Voigt, et al.
Published: (2012-11-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
by: Hendrikx JJMA, et al.
Published: (2020-10-01)

Clinical outcomes of intermittent panitumumab based-therapy for previously treated older patient with metastatic colorectal cancer: a case report and review of literature
by: Gerardo Rosati, et al.
Published: (2024-04-01)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
by: Jingquan Jia, et al.
Published: (2018-08-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
by: Vicente Alonso, et al.
Published: (2018-07-01)

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
by: Jörg Trojan, et al.
Published: (2015-01-01)

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
by: Antonio Marchetti, et al.
Published: (2014-01-01)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
by: Middleton, G, et al.
Published: (2013)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
by: Middleton, G, et al.
Published: (2013)

89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model
by: Logan D. Stone, et al.
Published: (2022-11-01)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
by: Yifan Xu, et al.
Published: (2018-11-01)

Panitumumab v terapii metastaticheskogokolorektal'nogo raka: dannye klinicheskikhissledovaniy, problema kozhnoy toksichnosti
by: E V Artamonova
Published: (2010-09-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
by: Liao MZ, et al.
Published: (2020-12-01)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
by: E Allen Sickmier, et al.
Published: (2016-01-01)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
by: Seymour, M, et al.
Published: (2013)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
by: Seymour, M, et al.
Published: (2013)